Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer
Authors
Keywords
-
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-01-06
DOI
10.1007/s00432-022-04459-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- (2022) F. Lordick et al. ANNALS OF ONCOLOGY
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
- (2021) U. Sahin et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Current Molecular Targeted Agents for Advanced Gastric Cancer
- (2020) Shanshan Nie et al. OncoTargets and Therapy
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
- (2019) O Türeci et al. ANNALS OF ONCOLOGY
- A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer
- (2018) Ugur Sahin et al. EUROPEAN JOURNAL OF CANCER
- Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study
- (2018) Siddesh V. Hartimath et al. Oncotarget
- Characterization of zolbetuximab in pancreatic cancer models
- (2018) Ӧzlem Türeci et al. OncoImmunology
- Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
- (2017) Prabhsimranjot Singh et al. Journal of Hematology & Oncology
- Second-line treatment of metastatic gastric cancer: Current options and future directions
- (2015) Dheepak Kanagavel WORLD JOURNAL OF GASTROENTEROLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Treatment options in patients with metastatic gastric cancer: Current status and future perspectives
- (2014) Ahmet Bilici WORLD JOURNAL OF GASTROENTEROLOGY
- Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy
- (2013) Isabela Pedroza-Pacheco et al. Cellular & Molecular Immunology
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells
- (2013) SARAH-KRISTIN MUELLER et al. ONCOLOGY REPORTS
- Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma
- (2011) Joshua M. Lang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals
- (2011) Özlem Türeci et al. GENE
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Claudin Family of Proteins and Cancer: An Overview
- (2010) Amar B. Singh et al. Journal of Oncology
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
- (2008) U. Sahin et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started